

Product Name: Sunitinib-d10
Cat. No.: GC48118

Cas. No. 1126721-82-1

SMILES CC1=C(/C=C2C(NC3=C\2C=C(F)C=C3)=O)NC(C)=C1C(NCCN(C([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])[2H])=O


Formula	C22H17D10FN4O2	M.Wt	408.5
---------	----------------	------	-------

Solubility	DMSO: Soluble	Storage	Store at -20°C
------------	---------------	---------	----------------

General tips	For obtaining a higher solubility , please warm the tube at 37 °C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.
--------------	---

Shipping Condition	Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request.
--------------------	--

Structure



Sunitinib-d₁₀ is intended for use as an internal standard for the quantification of sunitinib by GC- or LC-MS. Sunitinib is a small molecule inhibitor of receptor tyrosine kinases, including FLK1 ($K_i = 9$ nM), PDGFR β ($K_i = 8$ nM), and FLT3.^{1,2} It is at least 10-fold selective for FLK1 and PDGFR β over a variety of tyrosine kinases in a panel, including EGFR, Cdk2, Met, IGFR-1, Abl, and Src.² Sunitinib inhibits VEGF-dependent FLK1 and PDGF-dependent PDGFR β phosphorylation ($IC_{50}s = 10$ and 10 nM, respectively) as well as phosphorylation of FLT3 and FLT3 carrying the activating internal tandem duplication mutation (FLT3-ITD; $IC_{50}s = 250$ and 50 nM, respectively).^{1,2} It decreases VEGF- and FGF-induced proliferation of human umbilical vein endothelial cells (HUVECs; $IC_{50}s = 30$ and 700 nM, respectively) and reduces tumor growth in a variety of mouse xenograft models when administered at doses ranging from 20 to 80 mg/kg per day.² Formulations containing sunitinib have

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

been used in the treatment of gastrointestinal stromal tumors and metastatic renal cell carcinoma.

1.O'Farrell, A.M., Abrams, T.J., Yuen, H.A., et al.SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivoBlood101(9)3597-3605(2003) 2.Mendel, D.B., Laird, A.D., Xin, X., et al.In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: Determination of a pharmacokinetic/pharmacodynamic relationshipClin. Cancer Res.9(1)327-337(2003)

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA